Vanguard Group Inc. Buys 17,839 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Vanguard Group Inc. increased its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,115,162 shares of the company's stock after purchasing an additional 17,839 shares during the quarter. Vanguard Group Inc. owned approximately 5.53% of Tarsus Pharmaceuticals worth $117,117,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. R Squared Ltd bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth $53,000. HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth $207,000. Victory Capital Management Inc. purchased a new position in Tarsus Pharmaceuticals in the fourth quarter worth $223,000. Oppenheimer & Co. Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter valued at $227,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $249,000. Institutional investors own 90.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TARS shares. Jefferies Financial Group lifted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim reissued a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer increased their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $63.67.

Remove Ads

Tarsus Pharmaceuticals Trading Up 5.2 %

NASDAQ:TARS traded up $2.31 during trading hours on Friday, reaching $46.43. The company's stock had a trading volume of 781,138 shares, compared to its average volume of 682,663. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -12.19 and a beta of 0.94. The firm has a 50-day simple moving average of $48.17 and a 200-day simple moving average of $47.32. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,084 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the transaction, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. This represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 7,131 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the sale, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last quarter. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.